FFL
PCRX icon

Financial Freedom LLC’s Pacira BioSciences PCRX Stock Holding History

Financial Freedom LLC’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-867
Closed -$19.6K – 311
2026
Q1 		$19.6K Hold
867
– – 0.01% 237
2025
Q4 		$22.4K Hold
867
– – 0.01% 219
2025
Q3 		$22.3K Hold
867
– – 0.01% 226
2025
Q2 		$20.7K Hold
867
– – 0.01% 224
2025
Q1 		$21.5K Hold
867
– – 0.01% 225
2024
Q4 		$16.3K Hold
867
– – 0.01% 239
2024
Q3 		$13K Hold
867
– – 0.01% 255
2024
Q2 		$24.8K Hold
867
– – 0.01% 204
2024
Q1 		$25.3K Hold
867
– – 0.02% 203
2023
Q4 		$29.3K Hold
867
– – 0.02% 190
2023
Q3 		$26.6K Hold
867
– – 0.02% 193
2023
Q2 		$34.7K Hold
867
– – 0.02% 172
2023
Q1 		$35.4K Hold
867
– – 0.03% 164
2022
Q4 		$33.5K Buy
+867
New +$42.2K 0.02% 170

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Financial Freedom LLC's PCRX Position: Q2 2026 in Review

Financial Freedom LLC sold out of Pacira BioSciences (PCRX) in Q2 2026, closing a stake of 867 shares — an estimated $19.6K sold.

Financial Freedom LLC first reported a position in PCRX in Q4 2022 and held it in 14 quarters. The position peaked at $35.4K in Q1 2023. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Financial Freedom LLC reported no remaining Pacira BioSciences position as of Q2 2026 after selling out during the quarter.
  • Financial Freedom LLC sold 867 Pacira BioSciences shares in Q2 2026, an estimated $19.6K.
  • Financial Freedom LLC first reported a position in Pacira BioSciences in Q4 2022 and held it in 14 quarters.
  • Financial Freedom LLC's Pacira BioSciences position peaked at $35.4K in Q1 2023.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Financial Freedom LLC's 13F filing for Q2 2026, filed 6 Aug 2026.